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1. Introduction 
In 2007, a worldwide analysis was published that assessed the types of HPV infection found 
in women without cervical disease (1). Of the 291 million women suffered with cervical 
diseases around the world, it was found that 32% are infected with either HPV16 or HPV18, 
or both. Data regarding the HPV burden and incidence rates are available on the WHO/ICO 
Information Centre on HPV and Cervical Cancer Web site (http://www.who.int/ 
hpvcentre). However, HPV prevalence in different regions of Southern China is not 
mentioned in this website. Hence the diversity of HPV prevalence and distribution in 
Taiwan, Hong Kong, and various regions of China is the major focus in this chapter. 
In Hong Kong, HPV DNA has been detected in 4% of women in 1996 and in 11% in 2002 by 
utilizing polymerase chain reaction methods on cervical samples, the most common high-
risk (HR) HPV types identified being, in decreasing order, HPV 16, 58, 53, 18, 33, 45, and 52. 
Moreover, HPV 6 and 11, two types responsible for about 90% of genital warts, are among 
the most frequent HPV types found in Hong Kong population. In Taiwan, the five most 
common HPV types, also listed in decreasing order of frequency, are: HPV 16, 18, 58, 33, 
and 52 for women with cervical cancer, and HPV 16, 52, 58, 18, and 51 for women with 
normal cytology (2, 3). According to literature, there are, to date, fifty cities and provinces 
including Hong Kong and Taiwan whose predominant HPV types are already known. Table 
1 shows the prevalence of HR-HPV in different regions in China such as, Zhejiang Province, 
Tianjin City, Shanxi Province, Hong Kong (HK), Guangzhou, Shandong Province, 
Shenzhen, Fujian, Liaoning Province, Beijing, Gansu province, Shanghai, Sichuan province, 
Guangdong province, Shenyang City, and in Taiwan. HPV type 16 exhibits the highest 
incidence in majority of these regions except Zhejiang province, Guangzhou, Fujian 
province, and in Taiwan (3), where HPV 52 has the highest prevalence. However, an 
investigation by Jin et al. (2010) in the Tibet Autonomous Region (TAR) which included both 
Tibetan and non-Tibetan populations pointed out that the frequency of HPV 33 may be 
higher than HPV 16 for non-Tibetan people, with the order of frequency of HPV genotypes 
being 16, 58, 31, 33, and 52 for Tibetan people. Incidentally, HPV 58 is also the second most 
common HPV type found in Taiwan (2), Chengdu, Liaoning, Beijing, Shenzhen, Shenyang, 
Shanxi, and Hong Kong (Table 1). 
The three major HR-HPV types which can be deduced from Table 1 infect over 50% of 
patients in every city/region included in the list. In Taiwan (2), the TAR, Liaoning, 
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Shenzhen, and Shanxi, the order of frequency of HPV type is 16, 58 and 52, while the order 
that can be found in Shandong, Hong Kong, and Shenyan is 16, 52 and 58. Another 
combination of frequency order, namely, HPV 52, 16, and 58, has also been discovered in 
Taiwan (3), Guangzhou, and Zhejiang, whereas the order 16, 58, and 33 is inherent to 
Beijing, Shanxi, and Shenzhen (4). Both Chengdu and Shenyang (cancer cases) are 
represented by the order HPV 16, 58, and 18. Only cancer cases in Shanxi consist of the 
order 16, 58, and 56. To summarize, HPV 16, 52, and 58 are the three major types affecting 
87% of the geography that includes these selected areas. 
The relationship between geography and HPV types is demonstrated in Figure 1, with A~D 
corresponding to the distribution of HPV 16, 18, 52, and 58, respectively. Coastal areas in the 
southeast such as Taiwan and Hong Kong display a higher prevalence than inland cities. 
HPV prevalence may vary among different regions due to geographical separation, an 
example of which is Taiwan and Hong Kong. The political separation of Taiwan and Hong 
Kong most likely caused the HPV types diverse than mainland China. Moreover, the TAR is 
isolated by mountains from mainland China while Taiwan and Hong Kong are separated by 
sea. Thus, the lower number of HPV patients in the TAR compared with other regions can 
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Fig. 1. The prevalence of major HPV types in some of China areas, Hong Kong and Taiwan. 
Four different HPV types show as (A) HPV16 (B) HPV18 (C) HPV52 (D) HPV58 
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be attributed to population conservation. In Taiwan, from 52 HPV types screening, HPV type 
52 has the highest frequency (21.48% flowing HPV type 16, 58, 56, 39, 51, 18, 68, 31, 33, 59, 45, 
and 35(3) among HR-HPV types that is distinguish HPV combination compared to other 
regions. This also demonstrates the effect of geography despite Taiwan and China essentially 
being of the same ethnicity only partitioned over 60 years to affect two generations of people 
including marriage. The more independent, younger generation and their sexual culture are 
two major factors that cause the variations in HPV types distribution. 
Since the prevalence of HPV types in each age group can be linked to sexual behavior, it is 
reasonable to investigate the multiple HPV infection types that can be found in patients (Table 
2). In Taiwan, the multiple HPV infection rate is over 19%, only slightly lower than Hong 
Kong’s (22.8%) but distinctly higher compared to others. For instance, most of the 
cities/regions that belong to mainland China, specifically inland cities like Beijng, Shangdong, 
Shanxi, Shengyang, Shenzhen, and Zhejiang, possess only 4~5% multiple HPV infection rates. 
Only Guangdong province has 11.1% between inland and island; however, Guangdong 
province is closest to Hong Kong and is more well-developed than inland cities. In contrast to 
Hong Kong and Taiwan, the TAR is isolated from immigration and might have conservative 
social behaviors, resulting to the lowest fraction of multiple HPV types (1.3%).  
Regions\ 
HPV types 
(%) 
16 18 31 33 35 39 45 51 52 56 58 59 68 References 
Beijing 2.6 0.5 0.4 0.8 0.6 0.1 0.1 0.2 0.02 0.7 1.0 0.3 0.5 
(Zhao et al., 
2009) 
Chengdu, 
western 
China 
(Cancer) 
68.1 4.9 ND 0.7 ND ND 0.7 ND 2.8 ND 8.3 ND ND 
(Li et al., 
2011) 
Fujian 
province 
21.3 11.6 ND 11.2 ND ND ND ND 23.1 ND ND ND ND 
(Wu et al., 
2010) 
Gansu 
Province 
(Cancer) 
80.4 3.6 1.8 1.8 ND ND ND ND 3.6 ND 3.6 3.6 ND 
(Wu et al., 
2009) 
Guangdong 
province 
(Cancer) 
25.0 20.8 ND ND ND ND ND ND 20.8 ND ND ND ND 
(Lin et al., 
2008b) 
Guangzhou 1.19 0.68 1.16 0.59 0.07 0.32 0.24 0.14 2.6 0.27 1.07 0.15 0.39 
(Liu et al., 
2011) 
Hong Kong 1.24 0.99 0 0.25 0 0.04 0.15 0 1.16 0 1.03 0.09 0.23 
(Liu et al., 
2011) 
Hong Kong 
(Cancer) 
18.3 9.1 ND ND ND ND ND 8 18.3 ND 17.7 ND ND 
(Chan et al., 
2009a) 
Hong Kong 
(Cancer) 
43.2 4.8 3.2 3.2 0.8 0.8 1.1 0.5 9.1 0 5.9 0.8 0.8 
(Chan et al., 
2009b) 
Liaoning 
province 
(Cancer) 
19.64 1.8 3.03 4.6 1.03 1.59 0.29 0.77 6.4 0.61 8.39 ND ND 
(Sun et al., 
2010) 
Taiwan 
(Cancer) 
18.4 1.7 0.3 3.6 0.6 1.5 0.6 2.9 9.4 0.6 7.6 1.5 0.6 
(Chen et al., 
2006) 
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Regions\ 
HPV types 
(%) 
16 18 31 33 35 39 45 51 52 56 58 59 68 References 
Taiwan 13.4 4.6 3.2 5.8 1.6 3.7 1.8 6.0 10.4 3.7 7.6 1.2 1.4 
(Lin et al., 
2008a) 
Taiwan 13.69 6.27 3.52 3.42 0.95 8.46 2.38 8.17 21.48 9.03
12.3
6 
2.66 4.66 
(Wang et 
al., 2010) 
Tibetan 1.52 0.21 1.17 1.17 0.04 0.21 0.17 0.21 1.09 0.21 1.17 0.08 0.5 
(Jin et al., 
2010) 
Shandong 
Province 
3.61 1.46 0.85 1.46 0.21 0.42 0.21 0.21 2.34 1.27 1.7 0 2.76 
(Yuan et al., 
2011) 
Sichuan 
province 
(Cancer) 
41.6 3.2 1.1 ND ND ND 1.1 ND 2.1 2.6 1.1 ND ND 
(Wu et al., 
2008) 
Shanxi 
Province 
5.7 0.8 0.5 1.2 ND 0.6 0.6 0.6 1.2 0.8 3.2 0.3 0.2 
(Dai et al., 
2006) 
Shenyang 
City 
3.4 1 1 0.9 0.3 0.9 0.6 0.6 2.5 0.9 1.9 0.6 0.3 
(Li et al., 
2006) 
Shenzhen 
City 
2.5 1.4 1.5 0.3 0.4 1.5 0.7 0.6 2 1 1.6 0.9 0.5 
(Wu et al., 
2007) 
Shenzhen 
City 
(Cancer) 
29.7 18.9 5.4 9 6.3 ND 1.8 ND 1.8 3.6 18.9 9 ND 
(Shi et al., 
2006) 
Zhejiang 
Province 
2.5 0.8 0.8 0.8 0.2 0.3 0.3 0.9 3.1 0.4 2.1 0.7 1.0 
(Ye et al., 
2010) 
Table 1. The HR-HPV types distribution in China, Hong Kong and Taiwan  
Numerous investigations focused on HR-HPV due to its higher relationship to cervical 
cancer and high-grade squamous intraepithelial lesion. To survey high-risk and low-risk 
HPV, HR-HPV frequently found in women with ASCUS and CIN3/cervical cancer, and 
might be at least double frequencies than LR-HPV cases (Table 2). The average incidence of 
HR-HPV in population is over 10%, but an extremely high incidence has been found in 
CIN3/cervical cancer cases (Taiwan reports, Table 2). However, the LR-HPV prevalence 
might not be estimated correctly due to less LR-HPV types screening. A survey of 52 HPV 
types reported in Taiwan suggests that the prevalence of LR-HPV (37 types) and HR-HPV 
(15 types) is 10% and 5%, respectively (3). Other HPV reports listed less than 37 LR-HPV 
types and focused only on HR-HPV. The same HPV screening type but few LR-HPV 
screening types caused underestimation for the incidence of LR-HPV that showed in Table 
2. For example, incidences of LR-HPV in Beijing, Hong Kong, the TAR, Shandong, Shanxi, 
Shenyang, Shenzhen, and Zhejiang are 2.0, 2.4, 2.1, 1.7, 3.8, 6.4, 6.6, and 3.5, respectively, and 
5.8, 74.8, 7.1, 11.0, 12.2, 11.7, 12.2, and 10.2 for HR-HPV.  
To compare HPV infections in different geographies around the world, the data from IARC 
and Table1 combined into Appendix 1. For overall HPV infection rate, Kenya has the 
highest HPV prevalence (38.8%) region and Span has the lowest HPV infection (1.5%). The 
Asia region including, China, Hong Kong, Japan, Korea, Taiwan and Thailand, are around 
10~15% of overall infection rate except Thailand (4.8%). The most of developed countries, 
such as, Italy, Japan, Span, Sweden, UK, and USA are less HPV prevalence than most of the 
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developing countries and under-developed countries, such as Argentina, Honduras, Kenya 
and Nigeria. For East-Asia, like, China, Japan, Hong Kong and Taiwan, HPV type 52 is 
higher HPV incidence than HPV 16. Other regions, HPV type 16 is the major incidence. HPV 
type 51 is another typical case for geographic : HPV 51 is higher incidence than HPV 52 in 
Brazil, Costa Rica, Republic of Korea, Scotland, and USA. In China and Hong Kong, HPV 51 
is not significant prevalence in population. For top five prevalence of HR-HPV, HPV 16, 18, 
31, 52, 58 are found in most of the countries/regions but different orders. However, the 
geography separated populations to cause the diverse of HPV infection types can be 
deduced from Appendix 1.  
 
Regions\HPV types (%) 
Multiple 
HPV %
LR HR References 
Beijing 2.6 2.0 5.8 (Zhao et al., 2009) 
Guangdong province
(Cancer)
11.1 ND 7.4 (Lin et al., 2008) 
Hong Kong (Cancer) 22.8 2.4 74.8 (Chan et al., 2009) 
Taiwan 4.9 4.4 52.3 (Chen et al., 2006) 
Taiwan (Cancer) 19.9 70.4 29.6 (Chao et al., 2008) 
Taiwan (Cancer) 19.4 68.9 31.1 (Lai et al., 2008) 
Taiwan 4.5 10.0 5.0 (Wang et al., 2010) 
Tibetan 1.32 2.14 7.05 (Jin et al., 2010) 
Shandong Province 4.2 1.70 11.04 (Yuan et al., 2011) 
Shanxi Province 4.5 3.8 12.2 (Dai et al., 2006) 
Shenyang City 5.3 6.4 11.7 (Li et al., 2006) 
Shenzhen City 4.4 6.6 12.2 (Wu et al., 2007) 
Zhejiang Province 3.5 2.7 10.2 (Ye et al., 2010) 
Table 2. A list of Multiple HPV infection rate in individual region. 
2. Age related to HPV genotypes 
Based on our previous study of Taiwan cases, the prevalence of LR-HPV is diverse among 
different age groups. For instance, HPV 84 is found most frequently in the 20–29 age group, 
HPV 54 in the 30–39 age group, HPV 53 in the 40–49 age group, and HPV 72 in the over-50 
age group. When the range of HPV genotypes that could be identified among cases of 
multiple infections was examined, 38 HPV genotypes were found in the over-50 age group 
and 40 genotypes in the 40–49 age group. In addition, 41 HPV genotypes were identified in 
the 30–39 age group, while 42 genotypes were discovered in the 20–29 age group (3). HR-
HPV genotypes in Taiwan have the highest peak in the younger population (<20 years old, 
28.1%), subsequently decreasing as it moved from the 20-29 age group (26.7%), 30-39 age 
group (15.5%), and 40-49 (12.1%) age group, to the over-50 age group (10.4%). This pattern, 
however, is different from those found in other regions (Table 3). 
Based on the epidemiological distribution of HPV in Beijing city, the 30-34 age group has the 
highest HPV frequency, while the 25-29 and 50-54 age groups have the lowest (5). By 
contrast, according to Guangdong province cervical cancer cases, older women tended to 
have higher HPV infection rates, as evidenced by the 11.7%, 8.2%, 8.1%, and 3.4% rates 
representing the 51-60, 41-50, 31-40, and 21-30 age groups, respectively (6). For people in 
Guangzhou, a high HPV rate (15.1%) is evident in the 20-29 age group and lower HPV rates 
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(11.7% and 11.8%) can be observed in the 40-49 and over-60 age groups (7). However, there 
is no significant difference in HPV rates among age groups in Guangzhou. In Hong Kong, 
the 20-29 age group has the highest peak in both cancer report and population screening; 
however, the 40-49 age group had less HPV frequency (7, 8) which remains without clear 
explanation. In other south coast cities, namely, Shanghai and Shenzhen, the 20-29 age 
group also exhibited the highest HPV infection rate but in Shanghai only; an opposite trend 
was found in Shenzhen city, where a high infection rate manifested in older people (45-59 
age group). Two recent reports related to Shenzhen city have pointed out the discrepancy 
about HPV prevalence. One demonstrated an increased HPV infection along with elder 
people and another report mentioned the 25-29 age group is the lowest. However, Shenzhen 
city has many plants with numerous temporary residents and tertiary sector workers from 
other counties that might cause residential status being significantly associated with HPV 
positivity. 
 
Regions\Age 
Groups (%) 
A B C D E F G H References 
Beijing 
25-29
4.9%
30-34
8.2%
35-39 
7.1% 
40-44
7.5%
45-49 
6.4% 
50-54
4.9%
  
(Zhao et al., 
2009) 
Guangdong 
province (Cancer)
21-30
3.4%
31-40
8.1%
41-50 
8.2% 
51-60
11.7%
    
(Lin et al., 
2008) 
Guangzhou 
20-29
15.1%
30-39
14.2%
40-49 
11.7%
50-59
14.0%
≧60 
11.8%
   
(Liu et al., 
2011) 
Hong Kong 
20-29
13.0%
30-39
4.9%
40-49 
4.6% 
50-59
7.1%
≧60 
9.6% 
   
(Liu et al., 
2011) 
Hong Kong 
(Cancer) 
<26 
10.0%
26-30
14.0%
31-35 
9.5% 
36-40
6.0%
41-45 
5.6% 
46-50
7.5%
51-55
6.5%
>55 
3.5%
(Chan et al., 
2009) 
Taiwan 
<20 
28.1%
20-29
26.7%
30-39 
15.5%
40-49
12.1%
≧50 
10.4%
   
(Wang et al., 
2010) 
Tibetan 
19-29
9.2%
30-39
9.2%
40-49 
9.1% 
≧50 
9.1%
    
(Jin et al., 
2010) 
Shanxi Province
15-24
13.3%
25-34
7.5%
35-44 
20.5%
45-54
17.0%
55-59 
14.3%
   
(Dai et al., 
2006) 
Shanghai 
18-20
54.4%
21-30
26.4%
31-40 
30% 
41-50
32.0%
51-60 
31.0%
61-78
31.5%
  
(Zhang et al., 
2008) 
Shenyang City 
<25 
2.7%
25-34
11.8%
35-44 
12.5%
45-54
13.0%
55-59 
6.3% 
   
(Li et al., 
2006) 
Shenzhen City 
<25 
14.3%
25-34
16.2%
35-44 
15.2%
45-59
24.4%
    
(Wu et al., 
2007) 
Shenzhen City 
15-24
15.5%
25-29
17.7%
30-34 
12.6%
35-39
8.8%
40-44 
10.2%
45-49
15.3%
50-59
21.0%
 
(Wu et al., 
2010) 
Zhejiang Province
20-24
14.5%
25-29
9.3%
30-34 
8.4% 
35-39
10.7%
40-44 
10.7%
45-49
9.2%
50-54
14.4%
55-79
8.6%
(Ye et al., 
2010) 
Table 3. A list of HPV infection rates among different age groups  
Zhejiang province provided more interesting data (9) showing a similar low HPV frequency 
in each age group (Table 3). Although both the 20-24 and 50-54 age groups have slightly 
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higher rates, the highest (14.4%) and lowest (8.4%) frequencies indicated a less diverse range 
of HPV prevalence than in other cities/regions. For the north coast city of Shenyang, HPV 
infection rate initially increases with respect to age, starting from 2.7% for women <25 years 
old to 13% for women 45-54 years old, but then drops to 6.3% for the 55-59 age group. This 
pattern is unique among coastal cities and is compatible with the flat age-curves that have 
been described in other countries such as India and Africa (10). A flat age-curve indicates 
that young women are not infected with new HPV types more frequently than older women 
(11). The number of sexual partners as well as the husband’s extramarital sexual 
relationships are believed to be explanatory of this flat age-curve. For inland cities, the TAR 
has consisted of HPV prevalence around 9% in every age group. For Shanxi province, the 
35-44 age group has the highest peak of infection distribution (20.5%), followed by age 
groups 45-54 with 17.0%, 55-59 with 14.3%, 15-24 with 13.3%, and 25-34 with 7.5%. Finally, 
for Guangzhou, Hong Kong, Shenzhen, and Zhejiang, the age distribution of cervical HPV 
infection shows a bimodal curve in half of the regions, with a first peak at younger women, 
a lower prevalence plateau at middle-aged women, and a variable rebound at older ages 
(≧45 years). One explanation for this is sexual behavior, which is considered an important 
risk factor for HPV infection. On the other hand, HPV incidence associated with unmarried 
status along with a high peak of HPV infection suggests that younger, single women may 
have an increased possibility of encountering complicated sexual relationships (11). 
However, the lower prevalence plateau at middle-aged women may be caused by less 
sexual frequency and single sex partners for married Chinese women. 
3. HPV type distribution in invasive cervical cancer and high-grade 
squamous intraepithelial lesion 
Overall HPV prevalence in invasive cervical cancer (ICC) is 87%, ranging from 86% to 94% 
by region, according to literature. In Jiashan, data for the incidence of invasive cervical 
cancer (ICC) from 1998 to 2002 has been reported. Incidence rates of cervical cancer ranged 
from 2.4 per 100,000 women to 4.6 per 100,000 women in Guangzhou (12). Some areas have 
notably high cervical cancer incidence rates, such as in Yangcheng and Shanxi, where there 
is an estimated rate of about 81 per 100,000 women between 1998–2002 (12). Incidentally, the 
incidence rates for cervical cancer in Hong Kong, Singapore, and Taiwan are 9.6, 10.6, and 
18.6 per 100,000 women, respectively (13). Between these three regions, the incidence of 
cervical cancer is highest in Taiwan and is nearly double than Hong Kong’s. However, it has 
declined since 1993 to 2003.  
Tay et al. (2008) has reported the five most common HPV types in Taiwan to be, in 
decreasing frequency order: HPV 16, 18, 58, 33, and 52 for women with cervical cancer, and 
HPV 16, 52, 58, 18, and 51 for women with normal cytology (13). Due to a high HPV 
prevalence, the Taiwanese National Health Insurance launched a screening program in 1995 
for women aged 30 years old and above. This program included quality control monitoring 
and a training system for medical doctors, public health nurses, cytologists, and medical 
technicians. By 2001, the screening program has been estimated to reduce cervical cancer 
incidence by 29% and mortality by 50%, and has been shown to be cost-effective for 
Taiwanese public health (14). Upon analysis of HPV genotypes present in ICC, HPV 16 was 
found to be the most common type, rating 52% in Asia and 58% in Europe, while HPV18 
was the second most common type which rated from 13% in South/Central America to 22% 
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Table 4. Incidence of HPV infection related to ICC, HSIL and LSIL in China, Hong Kong and 
Taiwan 
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in North America (13). Other HPV types most commonly related to ICC were HPV 31, 33, 
35, 45, and 52. However, the prevalence of both HPV 58 and 52 were notably higher in ICC 
cases in Asia. For example, the prevalence of HPV 58 and 52 was found to be as important as 
the prevalence of HPV 16 and 18 in early cervical cancer patients as well as patients with 
advanced cervical cancer in Taiwan (15). As shown in Table 4, the frequency of HPV in 
HSIL, ICC, and CIN3 samples is higher than in ASCUS, LSIL, CIN1, and CIN2. 
In Beijing, 85.7% of CIN3 patients have been diagnosed with HPV infections similar to 93.3% 
of HSIL patients (Table 4). In ASCUS cases, only 56.0% involve HPV infection (5). In all of 
these cases, HPV 16 was found to be the most common type (2.6% overall; 39.1% of HPV-
positive women), followed by HPV 58 (1.0% overall) and HPV 33 (0.8% overall). For inland 
regions like Shandong and Shanxi province, CIN3/ICC patients have the highest HPV 
infection rate. HPV types 16, 52, 58, and 31 are the most prevalent HPV genotypes found in 
Shandong, whereas HPV 16, 58, 52, 33, and 18 are the predominant genotypes in Shanxi 
province (16, 17). In the TAR, HPV prevalence in HSIL cases is twice that of LSIL patients 
(Table 4). The descending order of HPV incidence among Tibetan women is HPV 16, 33, 58, 
31, 52, and 68 (18).  
For coastal areas like Fujian, Guangdong, Jiangxi, Liaoning, Shanghai, Shenzhen, and 
Taiwan, a similar prevalence of HPV types in ICC/CIN3 cases is observable (Table1 and 
Table 4). In Fujian province, HPV 16 (24.5%), HPV 33 (21.6%), and HPV 52 (19.6%) are the 
major genotypes present in CIN2/3 patients. In addition, HPV 16 (42.7%), HPV 18 (20.8%), 
and HPV 33 (12.5%) are also frequently found in squamous cell carcinoma (SCC) and 
adenocarcinoma (ADCA) (19). For Guangdong and Jiangxi, there is a significantly increased 
risk of elevating the CIN stage with high viral load. Thus, 68.8% of CIN1, 80.3% of CIN2, 
90.2%of CIN3 and 90.0% of CIS contain HR-HPV genotypes like HPV 16 (79.6%), HPV 58 
(5.92%), HPV 33 (3.29%), HPV 18 (1.97%), HPV 6 (1.97%), HPV 31 (1.31%), HPV 39 (1.31%), 
and HPV 68 (1.31%) (20). In Liaoning province, the most common HPV genotypes are HPV 
16, HPV 58, HPV 52, HPV 33, HPV 53, and HPV 31, occurring in 54.6% of ASCUS patients, 
64.1% of CIN, and 83.1% of ICC (21). For the island of Taiwan, the HPV prevalence for 
ASCUS, LSIL, HSIL, and squamous cell carcinoma are 41.2%, 76.9%, 87.5%, and 66.7%, 
respectively. The five high-incidence HPV genotypes are HPV 52, 18, 58, 53, and 70 in 
Taiwanese CIN2 patients (22). For Shanghai city, HPV viral load values in women with 
CINs and cervical cancer were calculated to be 68.8% in CIN1, 66.7% in CIN2, 76.5% in 
CIN3, and 94.1% in cervical cancer (23). For Shenzhen city, the incidence of HR-HPV 
genotypes increased with increasing severity of cervical lesions, such as 50.0% of CIN1, and 
74.0% of CIN2 /CIN3. However, the most common types were HPV52, 16, and 18 in CIN 
samples that are different with population screening which the most common genotypes are 
HPV 16, 52, 58, 31 and 39 (24).  
4. HPV vaccination in Southern China, Hong Kong, and Taiwan 
Based on statistical calculations to determine the link between HPV and cervical cancer, many 
strategies for the prevention of cervical cancer have been proposed, including vaccination in 
younger women and improved HPV screening in older women (25). Two HPV vaccines have 
been generated from the recombinant L1 protein into non-infectious capsids (virus-like 
particles, VLPs). Gardasil™ (Merck and Co, USA) already has approval for vaccination against 
HPV6/11/16/18 in several countries including Singapore and Hong Kong. The bivalent 
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vaccine, Cervarix™ (GlaxoSmithKline, Belgium), has also been approved in both countries. 
Both vaccines were developed for HPV16 and HPV18, which cause approximately 70% of all 
reported cervical cancer cases worldwide (26). Thus, the quadrivalent vaccine can be expected 
to prevent CIN-2 and CIN-3 (CIN-2,3), cervical cancer, as well as genital warts. However, HPV 
18 is less common than HPV 52 and 58 in places like China, Hong Kong, and Taiwan (Table 1) 
where there is no publicly funded vaccination program. Hence vaccination is voluntary and 
paid by individuals.  
HPV vaccination does not increase the clearance of established infections; therefore, young 
females are ideally targeted before the development of sexual behavior. Initiation of HPV 
vaccination in younger cohorts combined with HPV screening in older women is a good 
strategy for HPV prevention. In China and Taiwan, evaluation of HPV vaccination as 
primary care HPV and assessment of the threshold cost per vaccinated girl (CVG) became 
potential feasible strategies in public health. Singapore’s policy regarding the management 
of HPV can be a reference for China and Taiwan. In a cervical cancer awareness survey for 
Singaporean women aged 30-55 years in 2006, 80% have had at least one Pap smear 
although 25% did not fully understand the significance behind it (13). Furthermore, 80% 
were unaware of HPV. In Hong Kong, most women have never heard of HPV or its 
infection by sexual transmission (27). Thus, participants had no knowledge or means of 
understanding the link between cervical cancer and HPV infection. However, participants 
agreed to HPV vaccination for both themselves and their teenage daughters if a health 
department endorsement was provided. Another study demonstrated that 32% of 
participants accepted HPV vaccination prior to receiving an educational booklet, and that 
this number increased to 52% after reading the pamphlet (28). About 48% of women 
remained undecided or disagreed with vaccination after education; 84% were worried about 
the side effects of vaccination, and 63% of women augmented fear of earlier sexual activity 
and unsafe sex. In China, a population-based survey related to knowledge concerning HPV 
vaccination reported that 15.8% of women between the ages of 15–54 have never heard of 
HPV, of which 49% bewared that HPV was related to cervical cancer. Around 87% of 
women agreed to be vaccinated with the prophylactic HPV vaccine and, in addition, 88% of 
women expressed that they would like to have their daughters vaccinated (29). In rural 
Shanxi, 67% of surveyed women did not believe that they were at risk of HPV infection and 
cervical cancer, while 65% of women thought there would be no difference whether or not 
they were vaccinated. However, 98% of the surveyed women preferred to receive 
information about the HPV vaccine from doctors, nurses, and hospital staff rather than from 
family members or friends.  
To improve the coverage of vaccination programs, a low vaccine price is one important issue 
to consider, and 83% of the women hoped that health insurance or the government can 
cover all or part of vaccine-related costs (30). When asked about the vaccine cost, 42% of 
women said they are willing to pay USD 2.50 or less and 50% agreed to pay USD 2.50–14.00, 
while only 8% can afford to pay more than USD 15.00 (31). However, according to 
investigation conducted by Canfell et al. (2011), vaccination combined with once- or twice-
in-a-lifetime screening is sufficiently cost-effective with a CVG of USD 52. But the maximum 
vaccine unit cost per dose is USD 9.00-14.00 that is also implied by maximum CVG of $50–
54. Therefore, HPV vaccination is potentially feasible for Chinese women at a reasonable 
price. However, in order to sustain a wide vaccine coverage, vaccine price would be one of 
the largest barriers for promotion (31).  
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In terms of HPV vaccine safety, data from pharmaceutical companies responsible for 
bivalent and quadrivalent vaccines suggest that some patients could be expected to 
experience mild, transient vaccine-related side effects upon receiving the HPV vaccine (32, 
33). From reports, pain is the most frequently reported adverse effect, with a prevalence 
ranging from 83% to 93% in tested vaccine group (34). With the exception of pain, no 
differences in serious vaccine-related events were prominent between vaccine and placebo 
groups. Data regarding the long-term safety of these vaccines are not yet available. HPV 
vaccination tests also did not include pregnant women. Although incidence of spontaneous 
abortion occurred in 10% of the vaccine group, it also occured in 7% of the placebo group, 
hence there is no significant difference between the two groups (35). Similarly, results from 
the quadrivalent vaccine Phase III studies indicated no observable differences in relation to 
the incidence of spontaneous abortions, late fetal death, or congenital abnormal infants 
between both groups. Even women who became pregnant more than 30 days after vaccine 
administration did not contribute any statistical difference whatsoever (35). 
Currently, available vaccines contain HPV 16 and 18; however, HPV types 52 and 58 are 
more prevalent in Southeast Asia, especially in Hong Kong and Taiwan. Although, HPV16 
and 18 are major genotypes found in CIN3 and cervical cancer patients, HPV types 52 and 
58 also have high prevalence rate in cancer cases. For example, HPV types 52 and 58 have 
25% and 12.5% infection rate in Taiwan (15),  As shown in Table 1, the prevalence of HPV 52 
and HPV 58 in Chengdu, Fujian, Gansu, Guangzhou, Hong Kong, Liaoning, Taiwan, 
Shandong, Shanxi, Shenyang, Shenzhen, and Zhejiang is higher than HPV 18, 6, and 11. This 
indicates that bivalent and quadrivalent vaccines are only capable of covering a small part of 
prospective patients infected with HPV. The emerging question then is, Should women pay for 
HPV vaccines without understanding their HPV infection types or not? It is safe to say at the 
present time that a vaccination program, combined with HPV Pap smear screening, is 
necessary to avoid useless vaccine treatment. The prevalence of HPV 52 and HPV 58 is 
nearly equal to the frequency of HPV 16 in China, Hong Kong, and Taiwan whether in 
cervical cancer-related or population-based surveys (Table 1). Moreover, a 1997–2007 report 
in Hong Kong showed that aside from 68.0% of all histological groups combined, 62.6% of 
squamous cell carcinoma and 93.8% of adenocarcinoma and adenosquamous cell carcinoma 
were covered by HPV 16 and HPV 18. Hence if vaccines included HPV 52 and HPV 58, it 
could increase the coverage by 15.9% for cervical cancers overall, 18.4% for squamous cell 
carcinoma, and 4.1% for adenocarcinoma and adenosquamous cell carcinoma (8). To 
summarize, pharmaceutical companies should make an effort to include more high 
prevalence HPV types in the next generation of vaccines they develop.  
The limitations of vaccine programs must also be recognized, because HPV 16 and 18 
account for approximately 70% of all invasive cervical cancers in nine countries (36), 
excluding Chinese people. Thus, women should be advised that the HPV vaccine does not 
confer full protection against cervical cancer. To reduce the risk of HPV infection and 
cervical cancer, safe sexual practices, which include the use of condoms and routine Pap 
smear testing, are necessary. Another important issue is the HPV genotypes screening. 
There are over 100 different HPV types, but only 13 HR-HPVs were routine in Pap smear 
screening. In our previous data, 52 HPV genotypes were adopted to screen 10,543 cases, of 
which 1,021 involve HR-HPVs and 556 involve non-HR-HPVs. Our investigation supported 
more HPV genotypes prevalence than other literatures. Majority of existing reports focus on 
HR-HPV due to a high risk of cervical cancer associated with it. However, other LR-HPV 
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types may be valuable, especially when indicating the risk in women’s sexual behavior 
which could bring about a high chance of incurring HR-HPV infection in the future. Any 
HR-HPV/LR-HPV infection is worth to notice the cervical cancer possibility in women even 
HR-HPV is significant in ICC/CIN3 samples. Although there are little evidences to prove 
the relationship between LR-HPV and cervical cancer, we would like to point out the 
importance of LR-HPV screening, which could be useful to get rid of HPV attack, if the cost 
is reasonable for both HR-HPV and LR-HPV tests. 
5. Conclusion  
HPV 16, 52, and 58 are the most predominant types of HPV in China, Hong Kong, and 
Taiwan. HPV 18, on the other hand, may have lower prevalence than types 39, 51, and 56 in 
some regions, such as Taiwan. Single/multiple HPV infection types do not distinguish 
between different age groups. The incidence of HPV types reflect women’s sexual behavior 
in different ages. However, HPV 16 is clearly the most common type of HPV in the world. 
Because HPV 16, 52, and 58 are more common than HPV 18 in China, Hong Kong, and 
Taiwan, the protective effect of an HPV16/18 vaccine against HR-HPV infection in these 
regions should be a major consideration because both subtypes are not powerful enough to 
reduce the prevalence of cervical cancer. Geographic variation with regard to distribution of 
HPV genotypes should also be an important consideration, especially in the tailoring of 
vaccines in different regions. The prevalence of HPV genotypes may be caused by the 
complex interplay among different HPV genotypes, safety of sexual practices, and host 
immunogenetic factors.  
6. Appendix: The HPV prevalence around the world 
Area 
Overall
HPV (%)
HPV Genotypes (%) 
Reference 
6 11 16 18 31 33 35 39 45 51 52 56 58 59 68 73 82 
Argentina 16.7 0.1 0.3 4.0 1.9 1.8 1.4 1.9 1.0 1.1 0.4 1.2 0.9 1.3 0.8 0.8 0.2 0.1 
(Matos et 
al., 2003) 
Brazil 13.8 0.5 0.5 2.7 0.8 1.1 0.4 0.2 0.1 0.5 0.7 0.6 0.6 2.1 0.1 0.4 0.2 0.1 
(Franco et 
al., 1999) 
Chile 11.2 0.2 0.4 2.2 0.4 0.5 0.1 0.3 0.7 0.7 0.7 0.8 1.3 1.0 0.9 0.0 0.2 0.0 
(Ferreccio 
et al., 2004) 
China 
(Beijing) 
7.9 ND ND 2.6 0.5 0.4 0.8 0.6 0.1 0.1 0.2 0.0 0.7 1.0 0.3 0.5 0.1 ND 
(Zhao et al., 
2009) 
China 
(Guangzho) 
8.9 ND ND 1.2 0.7 1.2 0.6 0.1 0.3 0.2 0.1 2.6 0.3 1.1 0.2 0.4 ND ND 
(Liu et al., 
2011) 
China (HK) 5.2 ND ND 1.2 1.0 0.0 0.3 0.0 0.1 0.2 0.0 1.2 0.0 1.0 0.1 0.2 ND ND 
(Liu et al., 
2011) 
China 
(Shandong) 
16.5 ND ND 3.6 1.5 0.9 1.5 0.2 0.4 0.2 0.2 2.3 1.3 1.7 0.0 2.8 ND ND 
(Yuan et al., 
2011) 
China 
(Shanxi) 
15.9 ND ND 5.7 0.8 0.5 1.2 ND 0.6 0.6 0.6 1.2 0.8 3.2 0.3 0.2 ND 0.2 
(Dai et al., 
2006) 
China 
(Shenyang) 
14.8 ND ND 3.4 1.0 1.0 0.9 0.3 0.9 0.6 0.6 2.5 0.9 1.9 0.6 0.3 ND 0.2 
(Li et al., 
2006) 
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China 
(Shenzhen) 
15.2 ND ND 2.5 1.4 1.5 0.3 0.4 1.5 0.7 0.6 2.0 1.0 1.6 0.9 0.5 0.1 0.2 
(Wu et al., 
2007) 
China 
(Zhejiang) 
13.9 ND ND 2.5 0.8 0.8 0.8 0.2 0.3 0.3 0.9 3.1 0.4 2.1 0.7 1.0 0.0 ND 
(Ye et al., 
2010) 
China 
(Tibetan) 
7.8 ND ND 1.5 0.2 1.2 1.2 0.0 0.2 0.2 0.2 1.1 0.2 1.2 0.1 0.5 ND ND 
(Jin et al., 
2010) 
Costa Rica 22.4 0.4 0.2 2.2 1.1 1.1 0.5 0.2 0.4 0.5 1.5 1.1 0.5 1.3 0.3 0.2 0.3 0.3 
(Herrero et 
al., 2005) 
Ho Chi Minh. 10.9 0.0 0.0 3.3 1.2 0.8 1.1 0.3 0.9 0.7 0.8 1.1 1.1 1.5 0.0 0.7 0.1 0.0 
(Ahn et al., 
2003) 
Honduras 39.0 0.2 1.8 10.9 4.1 3.4 0.7 0.2 0.0 0.0 0.0 0.2 0.0 1.8 0.0 0.0 0.0 0.0 
(Ferrera et 
al., 1999) 
Italy 7.8 0.1 0.2 2.7 0.1 0.3 0.1 0.1 0.3 0.6 0.1 0.3 0.4 0.4 0.1 0.2 0.0 0.0 
(Ronco et 
al., 2005) 
Japan 10.2 0.1 0.0 0.5 0.2 0.3 0.4 0.8 0.1 0.0 0.9 1.2 0.6 0.2 0.2 0.5 0.0 0.0 
(Asato et 
al., 2004) 
Kenya 38.8 0.5 0.5 3.5 2.2 3.3 1.9 2.7 1.4 1.6 1.1 6.2 1.4 2.7 0.3 1.6 ND ND 
(De Vuyst 
et al., 2003) 
Mexico 13.5 0.5 1.0 1.8 1.1 1.5 1.0 0.3 1.0 0.6 0.8 0.8 0.3 1.0 0.2 0.3 0.1 0.3 
(Lazcano-
Ponce et al. 
2001) 
Nigeria 24.8 0.4 0.4 3.0 1.7 2.6 0.6 3.0 0.4 2.1 1.1 1.5 2.1 2.5 0.6 0.2 0.5 0.4 
(Thomas et 
al., 2004) 
Republic of 
Korea 
15.2 0.7 0.3 1.3 1.2 0.7 0.4 0.3 0.9 0.1 1.8 1.3 1.5 0.7 0.4 0.5 0.5 0.0 
(Shin et al., 
2004) 
Scotland 12.7 ND ND 3.4 1.4 0.7 0.5 0.3 0.4 0.9 0.9 0.8 0.6 0.7 0.7 0.2 0.8 0.1 
(Cuschieri 
et al., 2004) 
Senegal 12.5 0.2 0.0 1.0 0.9 0.4 0.7 0.0 0.1 0.2 0.3 0.5 0.3 0.7 0.4 0.1 0.3 0.1 
(Xi et al., 
2003) 
South India 14.0 0.2 0.0 2.8 0.8 0.8 0.8 0.8 0.6 0.3 0.4 0.7 1.1 0.2 0.7 0.0 0.2 0.2 
(Franceschi 
et al., 2005) 
Spain Hanoi, 
Vietnam 
1.5 0.1 0.0 1.0 0.0 0.4 0.0 0.5 0.1 0.0 0.4 0.0 0.2 0.1 0.2 0.2 0.0 0.0 
(de Sanjose 
et al., 2003) 
Sweden 6.8 ND ND 2.1 0.6 1.1 0.4 0.3 0.2 0.8. 0.4 0.3 0.5 0.3 0.1 ND ND ND 
(Forslund 
et al., 2002) 
Taiwan 15.0 0.5 0.1 1.4 0.6 0.3 0.3 0.1 0.8 0.2 0.8 2.1 0.9 1.2 0.3 0.1 0.2 1.6 
(Wang et 
al., 2010) 
Thailand 4.8 0.0 0.0 0.7 0.3 0.3 0.5 0.2 0.3 0.1 0.2 0.3 0.2 0.4 0.1 0.2 0.0 0.0 
(Sukvirach 
et al., 2003) 
UK 3.5 ND ND 1.3 0.7 0.9 0.7 ND ND ND ND ND ND ND ND ND ND ND 
(Cuzick et 
al., 1995) 
USA 15.8 0.6 0.6 2.5 0.8 0.9 0.6 0.3 0.7 0.9 1.8 0.8 0.5 0.9 0.7 0.2 0.0 0.0 
(Liaw et al., 
1999) 
 
Appendix 1. Data summarized from IARC and this article.  
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